Advances in Early Diagnostic Markers for Hepatocellular Liver Cancer

Mingqi Wang; Kehe Chen; Huanyao Li; Chunrou Qin

doi:10.54097/p1bxmg57

Authors

Mingqi Wang
Kehe Chen
Huanyao Li
Chunrou Qin

DOI:

https://doi.org/10.54097/p1bxmg57

Keywords:

Hepatocellular Carcinoma, Early Diagnosis, Tumor Markers

Abstract

Hepatocellular carcinoma (HCC) is a common malignancy in China, and its incidence and lethality are increasing every year, so it is especially important to choose cost-effective diagnostic methods to achieve early diagnosis and treatment. At present, the most widely used examination measures in the world are ultrasonography of the liver and tumor marker alpha-fetoprotein (AFP), but its accuracy is limited, the research on tumor markers of HCC has been progressing rapidly in recent years, and this paper summarizes the roles and values of protein markers, enzyme and its isozymes markers, and gene markers in the identification of early hepatocellular carcinoma.

Downloads

Download data is not yet available.

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660.

[2] Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021;134(7):783-791. doi:10.1097/CM9.0000000000001474.

[3] Li J, Gao T, Gu S, Zhi J, Yang J, Li G. An electrochemical biosensor for the assay of alpha-fetoprotein-L3 with practical applications. Biosens Bioelectron.2017;87:352-357. doi:10. 1016/ j. bios.2016.08.071.

[4] Marrero JA, Romano PR, Nikolaeva O, et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol. 2005;43(6):1007-1012. doi:. 10.1016/j. jhep. 2005.05.028.

[5] Zhang X, Wu LN, Li XQ, et al. Whether the Golgi protein 73 could be a diagnostic serological marker in hepatocellular carcinoma: a meta analysis. BMC Gastroenterol. 2023;23 (1): 85. doi:10.1186/s12876-023-02685-8.

[6] Jia X, Liu J, Gao Y, Huang Y, Du Z. Diagnosis accuracy of serum glypican-3 in patients with hepatocellular carcinoma: a systematic review with meta- analysis. Arch Med Res. 2014;45(7):580-588. doi: 10.1016/j.arcmed.2014.11.002.

[7] Wu M, Liu Z, Li X, Zhang A, Li N. Dynamic Changes in Serum Markers and Their Utility in the Early Diagnosis of All Stages of Hepatitis B-Associated Hepatocellular Carcinoma. Onco Targets Ther.2020;13:827 -840. doi:10.2147/OTT.S229835.

[8] Fu Y, Xu X, Huang D, et al. Plasma Heat Shock Protein 90alpha as a Biomarker for the Diagnosis of Liver Cancer: an Official, Large-scale, and Multicenter Clinical Trial. EBio Medicine. 2017;24:56-63. doi:10.1016/j.ebiom.2017.09.007.

[9] Gan Y, Liang Q, Song X. Diagnostic value of alpha-L-fucosidase for hepatocellular carcinoma: a meta-analysis. Tumour Biol. 2014;35(5):3953-3960. doi :10.1007/s13277-013-1563-8.

[10] Hu J, Xu Y, Shen ZZ, et al. High expressions of vascular endothelial growth factor and platelet-derived endothelial cell growth factor predict poor prognosis in alpha-fetoprotein-negative hepatocellular carcinoma patients after curative resection. J Cancer Res Clin Oncol. 2009;135(10):1359- 1367. doi:10.1007/s004. 1367. doi:10.1007/s00432-009-0577-5.

[11] Li C, Zhang Z, Zhang P, Liu J. Diagnostic accuracy of des-gamma-carboxy prothrombin versus alpha-fetoprotein for hepatocellular carcinoma: A systematic review. Hepatol Res. 2014;44(10): E11-25. doi:10.1111/hepr.12201.

[12] Ladeiro Y, Couchy G, Balabaud C, et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology. 2008;47(6):1955-1963. doi:10.1002/hep.22256.

[13] Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol. 2011;29(36):4781-4788. J Clin Oncol. 2011; 29 (36): 4781-4788. doi:10.1200/JCO.2011.38.2697.

[14] Peng C, Ye Y, Wang Z, et al. Circulating microRNAs for the diagnosis of hepatocellular carcinoma. Dig Liver Dis. 2019;51 (5): 621-631. doi:10.1016/j.dld.2018.12.011.

[15] Chen S, Zhang Y, Ding X, Li W. Identification of lncRNA/ circRNA-miRNA-mRNA ceRNA Network as Biomarkers for Hepatocellular Carcinoma. Front Genet.2022; 13: 838869 . doi:10.3389/fgene.2022.838869.

[16] Liang WC, Wong CW, Liang PP, et al. Translation of the circular RNA circβ-catenin promotes liver cancer cell growth through activation of the Wnt pathway. Genome Biol. 2019;20 (1): 84. doi:10.1186/s13059-019-1685-4.

[17] Yu J, Ding WB, Wang MC, et al. Plasma circular RNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma: A large-scale, multicenter study. Int J Cancer. 2020;146 (6): 1754-1763. doi:10.1002/ijc.32647.

[18] Zhang YJ, Wu HC, Shen J, et al. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res. 2007;13(8):2378-2384. doi:. 10.1158/1078-0432.CCR-06-1900.

[19] Kisiel JB, Dukek BA, V S R Kanipakam R, et al. Hepatocellular Carcinoma Detection by Plasma Methylated DNA: Discovery, Phase I Pilot, and Phase II Clinical Validation. Hepatology. 2019;69(3):1180-1192. doi:10.1002/ hep. 30244.